A5075962727- Clinical Nutrition and Gastroenterology
- Nutrition and Health in Aging
- Child Nutrition and Feeding Issues
- Gastric Cancer Management and Outcomes
- Muscle and Compartmental Disorders
- Electrolyte and hormonal disorders
- Diet and metabolism studies
- Abdominal Surgery and Complications
- Gastrointestinal motility and disorders
- Metabolism and Genetic Disorders
- Gastroesophageal reflux and treatments
- Potassium and Related Disorders
- Intestinal Malrotation and Obstruction Disorders
- Restless Legs Syndrome Research
- Inflammatory Myopathies and Dermatomyositis
- Metastasis and carcinoma case studies
- Pharmaceutical studies and practices
- Gastrointestinal Tumor Research and Treatment
- Frailty in Older Adults
- Enhanced Recovery After Surgery
- Hernia repair and management
- Body Contouring and Surgery
- Intestinal and Peritoneal Adhesions
- Intensive Care Unit Cognitive Disorders
- Drug Transport and Resistance Mechanisms
Hôpital Beaujon
2021-2025
Inserm
2021-2025
Université Paris Cité
2021-2025
Centre de Recherche sur l'Inflammation
2021-2025
Assistance Publique – Hôpitaux de Paris
2022-2023
Sorbonne Paris Cité
2023
Centre National de la Recherche Scientifique
2023
Hôpital Beau-Séjour
2022
Hôpital Bichat-Claude-Bernard
2021
Teduglutide, a GLP-2 analogue, has been available in France since 2015 to treat short-bowel-syndrome (SBS)-associated chronic intestinal failure (CIF) but it remains very expensive. No real-life data on the number of potential candidates are available. The aim this study was assess teduglutide initiation and outcomes SBS-CIF patients. All patients cared for an expert home parenteral support (PS) center between 2020 were retrospectively included. Patients divided into two subpopulations:...
The differences in outcomes after weaning off intravenous support (IVS) for chronic intestinal failure (IF) are unclear. Adult IF patients who weaned IVS at a tertiary care center (June 2019–2022) were included this study, and nutritional functional markers assessed before, during, weaning. Short bowel syndrome (SBS) was present 77/98 of the patients, with different according to final anatomy. body weight BMI increased during those jejunocolonic (JC) anastomosis (p < 0.001), but loss...
Introduction: SBS is the main cause of chronic intestinal failure. New treatments such as GLP-2 analogues aim at improving mucosal trophicity and absorption while reducing PN dependence. The was to identify factors determining weaning in children with SBS. Methods: A monocentric retrospective study involved all followed between 2015 2020. dependence defined non-protein calories (kcal/day)/ REE (kcal/day, from Schofield). Statistical analysis included non-parametric tests, Mann-Whitney Chi-2...
Introduction: Teduglutide (TED), a GLP-2 agonist, is effective to reduce Parenteral Nutrition (PN) dependence in patients with Short Bowel Syndrome (SBS), some heterogeneity of response between patients. PN reduction at 6 months TED treatment significantly associated patients’ oral intake baseline (1). We aimed study the impact food on efficacy longer term and evolution during treatment. Methods: This work was monocentric retrospective conducted an expert center PN. enrolled 49 SBS treated...
Introduction: Short bowel syndrome with intestinal failure (SBS-IF) requires use of parenteral support (PS) and highly impacts patients quality life. Teduglutide (TED), a GLP-2-analog, has proven efficacy reducing the need for PS. After publication two case reports describing development duodenal jejunal polyps in SBS treated TED (Ukleja 2018, Pevny 2020), we aimed to verify this risk cohort an expert center chronic failure. Methods: A retrospective study was conducted 35 teduglutide at...
Introduction: Short Bowel Syndrome (SBS) is a rare complex disease causing chronic intestinal failure (CIF) for which Parenteral Support (PS) the reference treatment. Teduglutide (TED), GLP-2 analogue, available and reimbursed in France since 2015 treatment of SBS-CIF patients. The cost this drug very high there no data about number potential candidates real life. aim study was to analyze real-life setting characteristics SBS patients treated with TED over time, evaluate percentage as well...
Introduction: TED, a GLP-2-analog, has proven efficacy reducing the need for Parenteral Nutrition (PN) in patients with SBS. However, there is some heterogeneity patients’ response to TED and mechanisms of action GLP-2 on intestinal cells are still poorly understood. The purpose study was explore treatment TED. Methods: For this purpose, biopsies 41 SBS treated collected before after initiation, were selected analyzed. mRNAs extracted from analyzed RNA sequencing. Statistical analyses...